CD274 and non-small cell lung carcinoma: Syukuya et al. reported that the landmark PFS correlated with the OS, with a longer landmark PFS at 24 weeks being the best predictor of the survival in patients with NSCLC treated with anti–PD-1/PD-L1 antibodies [16].